Gastrointestinal manifestations in CF patients, as detailed in Table 2, are either a direct consequence of the CFTR dysfunction or a secondary complication of the disease or therapy [37] in the intestinal epithelium, pancreatic and biliary ducts with viscous secretions and local inflammatory phenomena, all of which cause maldigestion, intestinal transit disorders and intestinal obstruction. The gene discussed is CFTR; the disease is cystic fibrosis.